Pfizer decides to continue development of GLP agonist Danuglipron | iPharmaCenterPfizer Progresses with Once-Daily Oral GLP-1 Receptor Agonist Danuglipron Pfizer has reported positive pharmacokinetic results from...
Obesity News | Overweight | Treatments |Updates | iPharmaCenterBoehringer Ingelheim has revealed its strategic plan to propel survodutide, a dual agonist for the glucagon/GLP-1 receptor, into three...
Diabetes mellitus News | iPharmaCenterSanofi has reduced the price of Lantus (insulin glargine injection) 100 Units/mL by 78%, which is Sanofi's most widely prescribed...
NASH News | Updates | Liver diseaseMay 26, 2022 FDA granted fast track designation for ervogastat/clesacostat for the treatment of NASH Pizer announced that the U.S. Food...
